Treatment Advances

October 24, 2024

Discover key insights into AML donor selection, HLA mismatch, and the role of donor age in improving transplant outcomes and reducing complications.

October 22, 2024

Learn how venetoclax and decitabine helped a higher percentage of senior AML patients achieve a complete reduction in AML signs/symptoms and reach transplant.

October 04, 2024

What is the NPM1 mutation in acute myeloid leukemia (AML)? How common is it and how is it treated? Learn answers to these questions!

September 17, 2024

Learn why the FDA requested another trial for Iomab-B and what this means for AML patients seeking new treatment options.

September 06, 2024

Revumenib gains FDA Priority Review for treating relapsed KMT2A-rearranged leukemia, with a decision expected by September 26, 2024.

August 06, 2024

Dr. Lancet shares the ongoing research at Moffitt Cancer Center for patients with acute myeloid leukemia.

July 15, 2024

TCR-T Therapies TSC-100 and TSC-101 were given FDA Designation in AML, ALL, and MDS.

June 25, 2024

Venetoclax, an oral BCL2 inhibitor, has shown promising efficacy in combination with less intensive therapies for older patients with AML.

June 12, 2024

Kura Oncology's ziftomenib for NPM1-mutated AML shows promise and is entering late-stage trials. Learn more about this targeted therapy and potential benefits.

May 13, 2024

Discover how Onureg aids in maintaining remission for Acute Myeloid Leukemia patients, backed by the latest NCCN Guidelines and clinical trial results.